Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Has Average Price Target of $21.33 According to Analysts

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) have been assigned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $21.33.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Anavex Life Sciences in a research report on Tuesday, September 8th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Anavex Life Sciences by 64.7% in the 1st quarter. Bank of America Corp DE now owns 863,150 shares of the biotechnology company’s stock valued at $2,650,000 after purchasing an additional 338,961 shares during the last quarter. Private Advisor Group LLC raised its position in shares of Anavex Life Sciences by 19.0% in the 1st quarter. Private Advisor Group LLC now owns 499,700 shares of the biotechnology company’s stock worth $1,534,000 after buying an additional 79,900 shares during the period. PVG Asset Management Corp raised its position in shares of Anavex Life Sciences by 51.4% in the 1st quarter. PVG Asset Management Corp now owns 327,544 shares of the biotechnology company’s stock worth $1,006,000 after buying an additional 111,249 shares during the period. Renaissance Technologies LLC boosted its holdings in Anavex Life Sciences by 988.8% in the first quarter. Renaissance Technologies LLC now owns 276,800 shares of the biotechnology company’s stock valued at $850,000 after acquiring an additional 251,378 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Anavex Life Sciences by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 247,849 shares of the biotechnology company’s stock valued at $761,000 after acquiring an additional 3,794 shares during the last quarter. Institutional investors and hedge funds own 31.55% of the company’s stock.

Key Anavex Life Sciences News

Here are the key news stories impacting Anavex Life Sciences this week:

• Neutral Sentiment: Several firms, including Rosen Law Firm, state that class actions have been filed on behalf of investors who purchased Anavex securities between November 26, 2025, and August 28, 2026. The November 30, 2026 deadline is for investors seeking appointment as lead plaintiff; it does not represent a finding that Anavex is liable. Rosen class action announcement
• Negative Sentiment: The lawsuits allege that Anavex and certain executives made misleading statements about the effectiveness of the company’s internal controls. According to the complaints, former CEO Christopher Missling certified the controls as effective before his termination for cause, while subsequent filings allegedly identified ineffective controls, a delayed filing, and a material weakness. These allegations are likely weighing on investor confidence and raise potential legal, financial, and governance risks. Levi & Korsinsky lawsuit reminder
• Negative Sentiment: The unusually large number of investor-law-firm alerts from October 6–7 may amplify negative sentiment even though the releases largely repeat the same underlying litigation news. Additional firms, including Kirby McInerney and Faruqi & Faruqi, are urging affected shareholders to contact them before the November 30 deadline. Kirby McInerney investor notice

Anavex Life Sciences Trading Down 4.4%

Shares of AVXL stock opened at $1.53 on Thursday. Anavex Life Sciences has a twelve month low of $1.51 and a twelve month high of $10.10. The company has a market capitalization of $141.83 million, a P/E ratio of -10.20 and a beta of 1.17. The business’s 50 day moving average is $2.76 and its two-hundred day moving average is $2.84.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, August 25th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.16. As a group, equities analysts predict that Anavex Life Sciences will post -0.33 earnings per share for the current fiscal year.

About Anavex Life Sciences

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biotechnology company focused on developing pharmaceutical therapies for central nervous system disorders. The company’s research is centered on small-molecule compounds intended to address cellular pathways associated with neurodegeneration and other neurological conditions.

Anavex’s lead product candidate is blarcamesine (ANAVEX2-73), an orally administered investigational therapy designed to activate the sigma-1 receptor and modulate muscarinic receptors.